Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12369)
All Articles published online
|
Publishing Process of This Article
|
Jul 26, 2017 (publication date) through Dec 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Patel N, Gluck J. Is Entresto good for the brain? World J Cardiol 2017; 9(7): 594-599 [PMID: 28824789 DOI: 10.4330/wjc.v9.i7.594] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v9/i7/594.htm |
| Number | Citing Articles |
| 1 |
Valerio Verdiani. Sacubitril/valsartan: from the PARADIGM-HF trial results to heart failure patients in internal medicine. A narrative review. Italian Journal of Medicine 2021; 15(1) doi: 10.4081/itjm.2021.1347
|
| 2 |
Peipei Wang, Ruixue Guo, Xiwen Bai, Wen Cui, Yiding Zhang, Huangmin Li, Jin Shang, Zhanzheng Zhao. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1034818
|
| 3 |
Florence Moulis, Vanessa Rousseau, Leila Chebane, Amandine Gouverneur, Louise Gaboriau, Jean-Luc Faillie, Geneviève Durrieu, François Montastruc, Jean-Louis Montastruc. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey. European Journal of Clinical Pharmacology 2018; 74(7): 983 doi: 10.1007/s00228-018-2460-2
|
| 4 |
Wei-Syun Hu, Cheng-Li Lin. Angiotensin Receptor-neprilysin Inhibitor Versus Renin-angiotensin System Inhibitor for Dementia Risk in Patients With Heart Failure. Journal of Cardiovascular Pharmacology 2023; 82(3): 229 doi: 10.1097/FJC.0000000000001451
|
| 5 |
Ping Lai, Jin-Hua Xue, Mu-Jin Xie, Jin-Hua Ye, Ke-Jun Tian, Jia-Yuan Ling, Wen-Ting Zhong, Dong Chen, Yi-Ming Zhong, Yong-Ling Liao. Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021. Medicine 2022; 101(31): e29398 doi: 10.1097/MD.0000000000029398
|
| 6 |
Amichai Perlman, Bruria Hirsh Raccah, Ilan Matok, Mordechai Muszkat. WITHDRAWN: Cognition and Dementia Related Adverse Effects with Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Journal of Cardiac Failure 2018; doi: 10.1016/j.cardfail.2018.04.009
|
| 7 |
Antonis S. Manolis, Theodora A. Manolis, Antonis A. Manolis, Helen Melita. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost. American Journal of Cardiovascular Drugs 2019; 19(1): 21 doi: 10.1007/s40256-018-0289-9
|
| 8 |
Mark Dayer, David H MacIver, Stuart D Rosen. The Central Nervous System and Heart Failure. Future Cardiology 2021; 17(2): 363 doi: 10.2217/fca-2020-0059
|
| 9 |
Anthony T Sharkey, Mohd Zaquan Ghafar, Shaun T O’Keeffe, Eamon C Mulkerrin. Angiotensin receptor neprilysin inhibitors in older patients with heart failure. BMJ Evidence-Based Medicine 2019; 24(1): 5 doi: 10.1136/bmjebm-2018-110949
|
| 10 |
Víctor Pérez-Roselló, María Batalla-Monedero, Ignacio Sánchez-Lázaro, Raquel López-Vilella, Pilar Sierra-San Miguel, Luis Almenar-Bonet. Three cases of psychosis after use of sacubitril/valsartan. Revista Española de Cardiología (English Edition) 2021; 74(1): 103 doi: 10.1016/j.rec.2020.05.033
|
| 11 |
Amichai Perlman, Bruria Hirsh Raccah, Ilan Matok, Mordechai Muszkat. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Journal of Cardiac Failure 2018; 24(8): 533 doi: 10.1016/j.cardfail.2018.04.010
|
| 12 |
Lin Liang, David Bin-Chia Wu, Mohamed Ismail Abdul Aziz, Raymond Wong, David Sim, Kui Toh Gerard Leong, Yong Quek Wei, Doreen Tan, Kwong Ng. Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. Journal of Medical Economics 2018; 21(12): 1148 doi: 10.1080/13696998.2018.1528979
|
| 13 |
Víctor Pérez-Roselló, María Batalla-Monedero, Ignacio Sánchez-Lázaro, Raquel López-Vilella, Pilar Sierra-San Miguel, Luis Almenar-Bonet. Tres casos de psicosis tras la toma de sacubitrilo-valsartán. Revista Española de Cardiología 2021; 74(1): 103 doi: 10.1016/j.recesp.2020.05.019
|
| 14 |
Michelle C. Johansen, Rebecca F. Gottesman. Cerebrovascular Disease and Cognitive Outcome in Patients with Cardiac Disease. Seminars in Neurology 2021; 41(04): 463 doi: 10.1055/s-0041-1726330
|